

20 January 2011

'RESEARCH NEVER STOPS'

[info@evotec.com](mailto:info@evotec.com) | [www.evotec.com](http://www.evotec.com)

For further information,  
please contact

**Dr Werner Lanthaler**  
*Chief Executive Officer*  
+49.(0)40.560 81-242  
+49.(0)40.560 81-333 Fax  
[werner.lanthaler@evotec.com](mailto:werner.lanthaler@evotec.com)

Evotec AG  
Schnackenburgallee 114  
22525 Hamburg (Germany)

## Evotec to Collaborate with Takeda Cambridge for Multi- target Hit Identification

**Hamburg, Germany – 20 January 2011:** Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.

Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR modeling software to identify and validate novel modulators against various targets selected by Takeda Cambridge.

**Dr Mario Polywka, Chief Operating Officer at Evotec stated:** "We are proud to be selected by Takeda Cambridge to collaborate on this important project. We have invested significantly in our world leading, hit-identification platform and this alliance further validates the strength of this platform and Evotec's ability to bring value to its partner's drug discovery efforts. We look forward to working with Takeda Cambridge."

**Dr Andrew Ayscough, Director of Chemistry at Takeda Cambridge, commented:** "We are pleased to have this opportunity to work with Evotec making use of their hit identification platform."

No financial details are disclosed.

### ABOUT EVOTEC AG

Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, oncology, inflammation and metabolic diseases. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Genentech, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression and an alliance in the field of diabetes with Andromeda (Teva). For additional information please go to [www.evotec.com](http://www.evotec.com).

### ABOUT TAKEDA CAMBRIDGE LTD

Takeda Cambridge Limited is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited in Osaka, Japan, and a drug discovery company specialising in identifying and validating novel drug targets and compounds. Takeda Cambridge and its subsidiary Takeda Singapore Pte Ltd

---

have developed a promising pipeline in key areas of unmet medical need such as CNS disorders and metabolic-related diseases. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

---

**FORWARD-LOOKING STATEMENTS** — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expected 2010 financial results and financial growth in 2011, our anticipated financing needs, our ability to deliver on our liquidity guidance, our belief that we are on course to sustainable profitability latest in 2012, our expectations and assumptions concerning regulatory, clinical and business strategies, the progress of our clinical development programmes and timing of the commencement and results of our clinical trials, strategic collaborations and management's plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally. The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*